东亚药业：子公司获CNAS实验室认可证书

Core Viewpoint - East Asia Pharmaceutical (605177) announced that its wholly-owned subsidiary, Hangzhou Shanli Biomedical Technology Co., Ltd., has recently obtained the laboratory accreditation certificate from the China National Accreditation Service for Conformity Assessment, which enhances the company's credibility and competitive edge in the market [1] Group 1 - The accreditation certificate is effective from May 20, 2025, to May 19, 2031, indicating a long-term recognition of the laboratory's management and technical capabilities [1] - This recognition allows Hangzhou Shanli's analysis laboratory to conduct testing according to national standards, thereby improving product quality and research capabilities [1] - The accreditation is expected to enhance customer trust and contribute to the company's high-quality development, although it will not have a significant impact on the company's current performance [1]